- Menstrual Migraine: A Review of Current Research and Clinical Challenges
-
Jong-Geun Seo
-
Headache Pain Res. 2024;25(1):16-23. Published online April 22, 2024
-
DOI: https://doi.org/10.62087/hpr.2024.0004
-
-
588
View
-
10
Download
-
1
Citations
-
 Abstract
 PDF
- The term “menstrual migraine” is commonly used to describe migraines that occur in association with menstruation, as distinct from other migraine types. A significant proportion of women of reproductive age experience migraine attacks related to their menstrual cycle. Menstrual migraine is characterized by migraine attacks occurring on day 1±2 (i.e., days −2 to +3) of menstruation in at least two out of three menstrual cycles. Although the reported prevalence of menstrual migraine varies considerably, population-based studies have found that menstrual migraine affects up to 60% of women with migraines. Several hypotheses have been proposed to explain the etiology of menstrual migraine, among which the estrogen withdrawal hypothesis is the most widely accepted. Women who experience menstrual migraines often face considerable disability due to perimenstrual attacks. Studies have reported that perimenstrual attacks are more severe and more difficult to manage. The principles of acute managing perimenstrual attacks are the same as those for managing nonmenstrual attacks. Short-term preventive therapy is needed to prevent menstrual migraines before they occur during the perimenstrual period. This review summarizes the prevalence, distinct clinical features, pathophysiological mechanisms, and management of menstrual migraine.
-
Citations
Citations to this article as recorded by  - Migraine in Women: Inescapable Femaleness?
Soo-Kyoung Kim
Headache and Pain Research.2024; 25(1): 1. CrossRef
- Zavegepant: Intranasal Drug for Acute Migraine Treatment
-
Jong-Geun Seo
-
Korean J Headache. 2023;24(1):17-19. Published online June 30, 2023
-
-
-
Abstract
PDF
- Calcitonin gene-related peptide (CGRP) is probably the most potent vasodilator in cerebral circulation. The new CGRP-targeted therapy for the treatment of acute treatment are now available for clinical practice. This review article summarized efficacy and safety of zavegepant, which is the first intranasal small molecule CGRP receptor antagonist for acute migraine treatment.
- Clinical Practice Guideline of Pharmacologic Treatment for Migraine Prevention in Adults 2021: The Committee of Clinical Practice Guideline of the Korean Headache Society
-
Kim Byung-Su, Jae Myun Chung, Pil-Wook Chung, Kwang-Yeol Park, Jin-Young Ahn, Heui-Soo Moon, Hong-Kyun Park, Dae Woong Bae, Jong-Geun Seo, Jong-Hee Sohn, Tae-Jin Song
-
Published online December 31, 2021
-
-
-
Abstract
PDF
- 성인 편두통 예방치료 약제 진료지침 2021: 대한두통학회 진료지침위원회
- A Case of Pneumocephalus after Lumbar Puncture in Spontaneous Intracranial Hypotension
-
Ayeong Jeong, Sung-Pa Park, Jong-Geun Seo
-
Published online December 31, 2021
-
-
-
Abstract
PDF
- 자발두개내압 저하에서 요추 천자 이후 발생한 공기머리증 1례
- Recurrent Cerebral Venous Thrombosis Associated with Antiphospholipid Syndrome
-
Ho-Cheol Lee, Sung-Pa Park, Jong-Geun Seo, Ph.D.
-
Published online June 30, 2019
-
-
-
Abstract
PDF
- 항인지질증후군과 연관된 재발성 뇌정맥혈전증
- A Case of Spontaneous Intracranial Hypotension Presented with Right Abducens Nerve Palsy
-
Wooryang Byun, Sung-Pa Park, Jong-Geun Seo
-
Published online June 30, 2016
-
-
-
Abstract
PDF
- 우측 외전신경마비를 동반한 자발두개내압저하에 기인한 두통
|
KHS
